Browsing by Author Johnson, Douglas B

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 12 of 12
Issue DateTitleAuthor(s)Citation
2015Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsKefford, Richard (Rick); Long, Georgina; Menzies, Alexander Maxwel; Pupo, Gulietta; Rizos, Helen; Scolyer, Richard; Thompson, John; Becker, Jurgen C; Berking, Carola; Eroglu, Zeynep; et al, Various; Gogas, Helen; Gutzmer, R.; Johnson, Douglas B; Sucker, Antje; Ye, Fei; Zhao, Shilin; Zimmer, Lisa; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: Pathology; Central Clinical School: SurgeryAcquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms, European Journal of Cancer, vol.51, 18, 2015,pp 2792-2799
2014Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor TherapyKefford, Richard (Rick); Long, Georgina; Chodon, Thinle; Dahlman, Kimberly; et al, Various; Guo, Rongqing; Hong, Aayoung; Hugo, Willy; Johnson, Douglas B; Kong, Xiangju; Koya, Richard; Moriceau, Gatien; Shi, Hubing; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreAcquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy, Cancer Discovery, vol.4, 1, 2014,pp 80-93
2017Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabCarlino, Matteo; Guminski, Alexander; Long, Georgina; Menzies, Alexander Maxwel; Park, John; Ramanujam, Sangeetha; Atkinson, V; Eroglu, Z; et al, Various; Johnson, Douglas B; Klein, O; McQuade, J; Shoushtari, A; Tsai, K. K.; Wong, Annie; Western Clinical School: Medicine (Westmead); Northern Clinical School: Medicine; Northern Clinical School: Medicine; Northern Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Melonoma & Skin Cancer Res. Inst.Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab, Annals of Oncology, vol.28, 2, 2017,pp 368-376
2014Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorKefford, Richard (Rick); Long, Georgina; Cebon, Jonathan Simon; et al, Various; Flaherty, Keith; Hamid, Omid; Infante, Jeffrey; Johnson, Douglas B; Kim, Kevin; McWilliams, Robert; Schuchter, Lynn; Sharfman, William; Weber, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreCombined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor, Journal of Clinical Oncology, vol.32, 33, 2014,pp 3697-3704
2018Immune checkpoint inhibitors in challenging populationsMenzies, Alexander Maxwel; Johnson, Douglas B; Sullivan, R; Northern Clinical School: MedicineImmune checkpoint inhibitors in challenging populations, Cancer, vol.123, 11, 2018,pp 1904-1911
2018Immune checkpoint inhibitors in challenging populationsMenzies, Alexander Maxwel; Johnson, Douglas B; Sullivan, R; Northern Clinical School: MedicineImmune checkpoint inhibitors in challenging populations, Cancer, vol.123, 11, 2018,pp 1904-1911
2018Immune checkpoint inhibitors in challenging populationsMenzies, Alexander Maxwel; Johnson, Douglas B; Sullivan, R; Northern Clinical School: MedicineImmune checkpoint inhibitors in challenging populations, Cancer, vol.123, 11, 2018,pp 1904-1911
2018Immune checkpoint inhibitors in challenging populationsMenzies, Alexander Maxwel; Johnson, Douglas B; Sullivan, R; Northern Clinical School: MedicineImmune checkpoint inhibitors in challenging populations, Cancer, vol.123, 11, 2018,pp 1904-1911
2018Immune checkpoint inhibitors in challenging populationsMenzies, Alexander Maxwel; Johnson, Douglas B; Sullivan, R; Northern Clinical School: MedicineImmune checkpoint inhibitors in challenging populations, Cancer, vol.123, 11, 2018,pp 1904-1911
2018Immune checkpoint inhibitors in challenging populationsMenzies, Alexander Maxwel; Johnson, Douglas B; Sullivan, R; Northern Clinical School: MedicineImmune checkpoint inhibitors in challenging populations, Cancer, vol.123, 11, 2018,pp 1904-1911
2018Immune checkpoint inhibitors in challenging populationsMenzies, Alexander Maxwel; Johnson, Douglas B; Sullivan, R; Northern Clinical School: MedicineImmune checkpoint inhibitors in challenging populations, Cancer, vol.123, 11, 2018,pp 1904-1911
2016Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune DisordersCarlino, Matteo; Guminski, Alexander; Long, Georgina; Menzies, Alexander Maxwel; Buchbinder, Elizabeth I; et al, Various; Johnson, Douglas B; Khushalani, Nikhil I; Lawrence, Donald; Mudigonda, Tejaswi; Ott, Patrick A; Puzanov, Igor; Sullivan, Ryan; Ye, Fei; Western Clinical School: Medicine (Westmead); Medicine Faculty Office; Central Clinical School: The Sydney Cancer Centre; Central Clinical School: MedicineIpilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders, JAMA Oncology, vol.2, 2, 2016,pp 234-240